Immutep to Participate at the Jefferies Healthcare Conference
June 07, 2023 08:00 ET
|
Immutep Limited
SYDNEY, AUSTRALIA, June 07, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3...
Immutep Reports Final Positive Data in 2nd Line Head and Neck Squamous Cell Carcinoma at ASCO 2023 Annual Meeting
June 05, 2023 08:00 ET
|
Immutep Limited
Media Release Efti plus pembrolizumab led to deep, durable responses, regardless of PD-L1 expression levels, and median Duration of Response not reached despite median follow up of 39 months in...
Immutep Successfully Completes Institutional Placement and Institutional Component of its Entitlement Offer
June 02, 2023 08:00 ET
|
Immutep Limited
Sydney, Australia, June 02, 2023 (GLOBE NEWSWIRE) -- Immutep Limited, an Australian company (ASX: IMM) (Nasdaq: IMMP) (Immutep or the Company), is pleased to announce the successful completion of an...
Immutep Selects Charles River Laboratories for IMP761’s GLP Toxicology Study
May 29, 2023 08:00 ET
|
Immutep Limited
Media Release Appointment of Charles River Laboratories ("Charles River") to run Immutep’s preclinical toxicology study evaluating the safety and toxicity of IMP761Forms a key step prior to...
Immutep Announces Publication of Abstracts for ASCO 2023 Annual Meeting
May 26, 2023 08:00 ET
|
Immutep Limited
Media Release New data published from Part C of TACTI-002 Phase II Trial evaluating eftilagimod alpha plus pembrolizumab in metastatic 2nd line head and neck squamous cell carcinomaDeep, durable...
Immutep Doses First Patient in AIPAC-003 Phase II/III Trial for Metastatic Breast Cancer
May 25, 2023 08:00 ET
|
Immutep Limited
Media Release SYDNEY, AUSTRALIA, May 25, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel...
Immutep Announces Promising New Clinical Data from Triple Combination Therapy in INSIGHT-003 Trial
May 24, 2023 08:00 ET
|
Immutep Limited
Media Release Efti plus standard-of-care anti-PD-1 therapy and doublet chemotherapy in 1st line non-small cell lung cancer is well tolerated and continues to show promising initial signals of...
Immutep’s Efti in Combination with Pembrolizumab Achieves Excellent Initial Overall Survival Benefit in 1st Line Non-Small Cell Lung Cancer
May 17, 2023 08:00 ET
|
Immutep Limited
Media Release Immuno-oncology combination of eftilagimod alpha (efti) and the leading anti-PD-1 therapy generates meaningful long-term survival in non-small cell lung cancer patients in Phase II...
Immutep Receives Positive Feedback from FDA on Late-Stage Clinical Development of Eftilagimod Alpha in Non-Small Cell Lung Cancer
May 16, 2023 08:00 ET
|
Immutep Limited
Media Release SYDNEY, AUSTRALIA, May 16, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel...
Immutep to Participate in the JMP Securities Life Sciences Conference
May 09, 2023 08:00 ET
|
Immutep Limited
Media Release SYDNEY, AUSTRALIA, May 09, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel...